Oncotelic Therapeutics, Inc.
OTLC evidence brief
What we can confirm
- BioSniper Score:
- 8.0 / 10
- Market Cap:
- $13.7M
- Lead Asset:
- al-101
What it means
What to watch
Prepared research question
What matters most for OTLC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OTLC
Oncotelic Therapeutics, Inc. (OTLC) is a clinical-stage biopharmaceutical company developing oncology, immunotherapy, and CNS drugs, with a pipeline including antisense, vascular disrupting, and nanoparticle formulations, and reported total revenue of $0.2M and net income of $0.4M as of 2026-06-30 [sec].
Key risk: Minimal revenue
BioSniper Score
Based on 4 of 6 signals
Market Cap
$13.7M
Cash Runway
—
Lead Asset
al-101
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates for Oncotelic Therapeutics, Inc..
Oncotelic Therapeutics, Inc. (OTLC) is a clinical-stage biopharmaceutical company developing oncology, immunotherapy, and CNS drugs, with a pipeline including antisense, vascular disrupting, and nanoparticle formulations, and reported total revenue of $0.2M and net income of $0.4M as of 2026-06-30 [sec].
- Reported total revenue of $0.2M and net income of $0.4M as of 2026-06-30 [sec].
- Shareholders' equity stood at $264.6M as of 2026-06-30 [sec].
- Lead candidate OT-101 (Trabedersen) is a Phase 2 antisense oligodeoxynucleotide targeting TGF-β2 for multiple cancers and has Orphan Drug status [pipeline].
- Deciparticle™ nanoparticle platform validated by a peer-reviewed publication supporting Sapu003 (IV everolimus) development [news · 2026-07-22].
- PDAOAI™ AI platform indexes 28 million PubMed abstracts and was featured at Qdrant Vector Space Day 2026 [news · 2026-06-08].
What works
- Multiple pipeline candidates (OT-101, OXI4503, CA4P) have Orphan Drug designations, providing regulatory and market exclusivity benefits [pipeline].
- Peer-reviewed validation of the Deciparticle™ platform supports a novel drug delivery approach for hydrophobic therapeutics [news · 2026-07-22].
- The PDAOAI™ AI platform, indexing 28 million PubMed abstracts, may enhance drug discovery efficiency [news · 2026-06-08].
- Expanded international IP coverage for OT-101 strengthens protection across neurology, oncology, and CNS drug delivery [news · 2026-02-12].
What to weigh
- Total revenue is minimal ($0.2M as of 2026-06-30) with no approved marketed products generating significant sales [sec].
- Pipeline candidates face intense competition; for example, OT-101's pancreatic cancer indication has 71 competitors including Genentech and Revolution Medicines [pipeline].
- Several candidates (e.g., CA4P) are still in preclinical stages, indicating long timelines to potential commercialization [pipeline].
- The company relies on partnerships (e.g., Sapu Nano) and external validation for key platform technologies, which may introduce dependency risks [news · 2026-07-22].
From the filings
Quoted directly from source documents.
OT-101 is a Phase 2 antisense oligodeoxynucleotide targeting TGF-β2 with Orphan Drug status.
“Pipeline Candidate: ot-101 Generic Name: Trabedersen Indication: Pancreatic carcinoma, malignant melanoma, colorectal carcinoma, high-grade glioma, and other TGF-β2 overexpressing malignancies Phase: Phase 2 Mechanism of Action: Antisense oligodeoxynucleotide targeting TGF-β2 Regulatory Status: Orphan Drug”
Deciparticle™ platform validated by peer-reviewed publication supporting Sapu003.
“Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)”
News · July 22, 2026
PDAOAI™ platform indexes 28 million PubMed abstracts.
“PDAOAI Platform Indexes 28 Million PubMed Abstracts on Qdrant; Introduces Manifold Folding to Solve the Infinity Problem in Biomedical Knowledge Retrieval”
News · June 8, 2026
Risks & what to watch (4)›
Key risks
- Minimal revenue — Total revenue of $0.2M as of 2026-06-30 with no approved product sales [sec].
- Intense pipeline competition — OT-101 faces 71 competitors in pancreatic cancer, including Genentech and Revolution Medicines [pipeline].
- Early-stage candidates — CA4P is preclinical; OXI4503 is Phase 2; long path to market [pipeline].
- Platform dependency on partners — Deciparticle™ platform relies on Sapu Nano collaboration for validation and development [news · 2026-07-22].
What to watch
- Clinical progress of OT-101 (Phase 2) and OXI4503 (Phase 2) in their respective indications [pipeline].
- Commercial launch timeline of the PDAOAI™ AI-enabled robotics platform [news · 2026-04-30].
- Further regulatory milestones for Deciparticle™-based Sapu003 [news · 2026-07-22].
- Financial sustainability given minimal revenue and reliance on partnerships [sec].
Sources: News · Pipeline · Generated October 12, 2026 · How we verify sources →
Run Oncotelic Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Oncotelic Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.50 · 5% dilution
Lead: Phase 2
4 candidates
No upcoming catalysts tracked
7 buys · 0 sells (180d)
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Jun 2021Institutional holders
1
Total value held
$12K
| Holder | Shares | Value |
|---|---|---|
| ifp advisors, inc | 61,196 | $12K |
Short Interest
as of May 22, 2026- % of float
- 2.5%
- Days to cover
- 8.0
- Shares short
- 662,753
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OTLC short interestGovernance
Frequently asked questions
What is the AI investment thesis for Oncotelic Therapeutics, Inc.?
Oncotelic Therapeutics, Inc. (OTLC) is a clinical-stage biopharmaceutical company developing oncology, immunotherapy, and CNS drugs, with a pipeline including antisense, vascular disrupting, and nanoparticle formulations, and reported total revenue of $0.2M and net income of $0.4M as of 2026-06-30 [sec].
Who is the CEO of Oncotelic Therapeutics, Inc.?
Dr. Vuong Trieu Ph.D. is the chief executive officer of Oncotelic Therapeutics, Inc. (OTLC).
Where is Oncotelic Therapeutics, Inc. headquartered?
Oncotelic Therapeutics, Inc. (OTLC) is headquartered in Agoura Hills, CA, United States.
What therapeutic areas does Oncotelic Therapeutics, Inc. focus on?
Oncotelic Therapeutics, Inc. develops therapies across Oncology, Neurology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.